N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

References

• Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–15. doi:10.1146/annurev-med-050311-201823.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00470-8.
   PubMedGoogle Scholar
• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. doi:10.1056/NEJMoa1002965.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16:315–37. Available from. doi:10.1038/nrd.2016.268.
   PubMed Web of Science ®Google Scholar
• Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659–71. doi:10.1080/19420862.2016.1156829.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90. doi:10.1158/0008-5472.CAN-08-1776.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70. doi:10.1158/1078-0432.CCR-04-0789.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-laford HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–35. doi:10.1038/nbt.3212.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–22. doi:10.1016/S1470-2045(17)30604-6.
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44. doi:10.1200/JCO.1996.14.3.737.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol. 2018;81:505–14. doi:10.1007/s00280-017-3510-7.
   PubMed Web of Science ®Google Scholar
• Grimsley GR, Scholtz JM, Pace CN. A summary of the measured pK values of the ionizable groups in folded proteins. Protein Sci. 2009;18:247–51. doi:10.1002/pro.19.
   PubMed Web of Science ®Google Scholar
• Wu G, Gao Y, Liu D, Tan X, Hu L, Qiu Z, Liu J, He H, Liu Y. Study on the heterogeneity of T-DM1 and the analysis of the unconjugated linker structure under a stable conjugation process. ACS Omega. 2019;4:8834–45. doi:10.1021/acsomega.9b00430.
   PubMedGoogle Scholar
• Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput. 2011;7:525–37. doi:10.1021/ct100578z.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17:114–24. doi:10.1021/bc0502917.
   PubMed Web of Science ®Google Scholar
• Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran -T-T, Ho W-H, Farias S, Casas MG, Abdiche Y, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20:161–67. doi:10.1016/j.chembiol.2013.01.010.
   PubMed Web of Science ®Google Scholar
• Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, Yang P, Morrison K, Coleman J, Malik F, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78:2115–26. doi:10.1158/0008-5472.CAN-17-3202.
   PubMed Web of Science ®Google Scholar
• Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen B-Q, Du X, Saad O, Bowles K, Olsen S, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123–33. doi:10.1158/1078-0432.CCR-14-2093.
   PubMed Web of Science ®Google Scholar
• Thompson P, Bezabeh B, Fleming R, Pruitt M, Mao S, Strout P, Chen C, Cho S, Zhong H, Wu H, et al. Hydrolytically stable site-specific conjugation at the N-terminus of an engineered antibody. Bioconjug Chem. 2015;26:2085–96. doi:10.1021/acs.bioconjchem.5b00355.
   PubMedGoogle Scholar
• Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 2014;95:558–64. doi:10.1038/clpt.2014.24.
   PubMed Web of Science ®Google Scholar
• Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, Smitt MC, Krop IE. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014;32:2750–57. doi:10.1200/JCO.2013.54.4999.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21. doi:10.1056/NEJMoa1914510.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–84. doi:10.1038/nbt832.
   PubMed Web of Science ®Google Scholar
• Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992;52:127–31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1727373
   PubMed Web of Science ®Google Scholar